
The US-headquartered company aimed to raise more than US$100 million and planned to file its listing application as early as next year, according to founder Zhang Jian.
“We want to expand our business in [mainland] China, and Hong Kong – as an international financial centre with a globally recognised stock exchange – is the natural choice for our listing,” Zhang said in an interview on the sidelines of MedTech World Asia in Hong Kong on Thursday.
Sir Run Run Shaw Hospital is a target customer, following regulatory approval from China’s drug regulator in November last year.
In Hong Kong, Prince of Wales Hospital had purchased Noah Medical’s equipment, Zhang said.
Currently, 90 per cent of the company’s revenue is generated in the United States, where surgical robots have treated about 15,000 patients.

Don't Miss:
-
China needs monkeys: lab animal shortage could hinder biotech growth
-
Trump slams Australia’s social media crackdown as ‘extortion’
-
Hong Kong a ‘2-way springboard’ between mainland China and world: John Lee
-
Taiwan waits for its new F-16s, still stuck in Hawaii after a fortnight’s delay
-
Singapore police question 5 over racist comments on Nepal floods, Air India investment

Khazak President Tokayev’s Influence may extend beyond his Term
Philippines Pushes back as China narrative on Batanes Grows
US-South Korea Alliance Faces a Test beyond Political Rhetoric